Abstracts
29 May 2009

Gemtuzumab ozogamicin

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
169
Views
178
Downloads

Authors

Treatment outcome for acute myeloid leukemia (AML) has substantially improved over the last decade, especially in patients younger than 60 years of age who can tolerate intensified treatment strategies including hematopoietic stem cell transplantation.1 On the other hand, there has been little progress in the treatment of older patients where intensive chemotherapy regimens are associated with a lower complete remission (CR) rate, an increased risk of relapse and an inferior overall survival.2-3 Factors which have been considered important in explaining the adverse effect of age include: 1) reduced ability of older patients to withstand the morbidity associated with chemotherapy-induced marrow hypoplasia; 2) concurrent medical problems; 3) unfavourable biologic profile of the disease as documented by a high proportion of patients presenting with adverse cytogenetics, preexisting myelodysplasia, stem cell and chemoresistant phenotype.

Altmetrics

Downloads

Download data is not yet available.

Citations

Supporting Agencies

How to Cite